Humana Inc. (NYSE:HUM) Downgraded to Sell at Zacks Investment Research
Zacks Investment Research cut shares of Humana Inc. (NYSE:HUM) from a hold rating to a sell rating in a research note published on Thursday.
According to Zacks, “Humana suffers severely from stiff competition, regulatory uncertainty and weakness in individual commercial business that has been bothering since long. Nevertheless, the shares gained 36.5%, against the industry’s increase of 36%, in last one year. The company grows on consistent revenue generation which also drives solid margin growth. For full-year 2017, it expects non-GAAP adjusted earnings per diluted common share guidance of at least $11.10. The strong revenue base is primarily attributable to accretive acquisitions. The company’s Medicare business has not only been excelling but also holds better long term prospects. Humana’s sound balance sheet led to frequent capital deployment. In addition, Humana’s several business diversification initiatives also paves way for long-term growth. The company is slated to report its second quarter results on Aug 2, before the market opens.”
Several other brokerages have also recently commented on HUM. Cowen and Company reissued a buy rating and set a $230.00 price target on shares of Humana in a research report on Friday, July 14th. Piper Jaffray Companies reissued a buy rating and set a $246.00 price target on shares of Humana in a research report on Friday, July 14th. Credit Suisse Group reissued an outperform rating and set a $250.00 price target (up from $245.00) on shares of Humana in a research report on Thursday, July 13th. Cantor Fitzgerald reissued a neutral rating on shares of Humana in a research report on Friday, June 23rd. Finally, Bank of America Corporation boosted their price target on shares of Humana from $270.00 to $275.00 and gave the stock a buy rating in a research report on Friday, July 14th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of $236.00.
Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, May 3rd. The insurance provider reported $2.75 EPS for the quarter, topping the consensus estimate of $2.55 by $0.20. Humana had a net margin of 2.71% and a return on equity of 14.38%. The firm had revenue of $13.76 billion for the quarter, compared to analysts’ expectations of $13.61 billion. During the same period in the previous year, the firm posted $1.86 EPS.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.watchlistnews.com/humana-inc-nysehum-downgraded-to-sell-at-zacks-investment-research/1463799.html.
In other Humana news, CEO Bruce D. Broussard sold 118,231 shares of the stock in a transaction that occurred on Thursday, May 4th. The shares were sold at an average price of $225.82, for a total transaction of $26,698,924.42. Following the transaction, the chief executive officer now owns 171,170 shares in the company, valued at approximately $38,653,609.40. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Timothy S. Huval sold 13,939 shares of the stock in a transaction that occurred on Thursday, May 4th. The stock was sold at an average price of $225.86, for a total transaction of $3,148,262.54. Following the transaction, the vice president now owns 23,639 shares in the company, valued at approximately $5,339,104.54. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 143,241 shares of company stock worth $32,446,903. Company insiders own 0.80% of the company’s stock.
Several hedge funds have recently modified their holdings of the company. Baldwin Brothers Inc. MA increased its stake in shares of Humana by 2.7% in the first quarter. Baldwin Brothers Inc. MA now owns 67,441 shares of the insurance provider’s stock worth $13,902,000 after buying an additional 1,782 shares during the period. ProShare Advisors LLC increased its stake in shares of Humana by 15.8% in the first quarter. ProShare Advisors LLC now owns 17,297 shares of the insurance provider’s stock worth $3,566,000 after buying an additional 2,356 shares during the period. Capstone Asset Management Co. increased its stake in shares of Humana by 2.0% in the first quarter. Capstone Asset Management Co. now owns 16,805 shares of the insurance provider’s stock worth $3,464,000 after buying an additional 334 shares during the period. Granite Investment Advisors LLC increased its stake in shares of Humana by 12.1% in the first quarter. Granite Investment Advisors LLC now owns 2,410 shares of the insurance provider’s stock worth $497,000 after buying an additional 260 shares during the period. Finally, World Asset Management Inc increased its stake in shares of Humana by 17.9% in the first quarter. World Asset Management Inc now owns 17,324 shares of the insurance provider’s stock worth $3,571,000 after buying an additional 2,628 shares during the period. 99.62% of the stock is owned by institutional investors.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.